pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,359 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT833Endpoints636BioPharma Dive243onclive165BioSpace96Fierce Biotech96raps37globenewswire health
therapy area
allOncology5001Rare Disease846Cardiology797Hematology768Immunology729Psychiatry & CNS582Pulmonology
  • Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
    Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.
    BioPharma Dive · 11d ago↗ source
  • 2026 IPO class blooms again as BlossomHill, Latigo set sights on Nasdaq
    Eighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the pandemic-driven high of 2021.
    BioSpace · 11d ago↗ source
  • Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
    The FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…
← prev
page 11 of 55
next →
28
fda recalls22
fda press21
fda medwatch17
570
Vaccines515
Endocrinology & Metabolism290
Ophthalmology255
Infectious Disease252
Nephrology238
BioSpace · 11d ago
↗ source
  • STAT+: Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer
    Bristol Myers Squibb is the third drugmaker in nine months to announce it is building the largest AI supercomputer in the life sciences industry.
    STAT · 11d ago↗ source
  • Opinion: My husband’s suicide shows there’s something very wrong with the U.S. insurance industry
    “My love for Randy and my professional experience were not enough to save him,” a physician writes about her husband’s suicide.
    STAT · 11d ago↗ source
  • STAT+: Telemedicine company touted by Novo Nordisk stressed profits over patient safety, ex-workers say
    LifeMD, a popular telehealth company, has been accused by former employees of pressing clinicians to mete out prescriptions more rapidly without sufficient screening and follow-up.
    STAT · 11d ago↗ source
  • STAT+: State audit of Medicaid records points to methods used by PBMs to obscure drug costs
    An audit of state Medicaid records revealed how PBMs are using complicated tactics for handling prescription drug claims that ultimately overcharge taxpayers.
    STAT · 11d ago↗ source
  • Opinion: It’s time to treat pandemics as threats to national security
    “Pandemics should be viewed and combated as threats to national security,” write David Blumenthal and James A. Morone.
    STAT · 11d ago↗ source
  • Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
    After the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape wi…
    BioSpace · 11d ago↗ source
  • How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
    Poised to become the first company to achieve a regulatory filing for a cell therapy in autoimmune disease, Kyverna Therapeutics is building a pipeline-in-a-product to change the treatment paradigm.
    BioSpace · 11d ago↗ source
  • Relay Peak Research LLC Recalls Zen Principle® Moringa Capsules Because of Possible Health Risk
    Relay Peak Research LLC (Zen Principle Naturals) of Incline Village, NV is voluntarily recalling its Zen Principle® brand Moringa Capsules dietary supplement because the product has the potential t…
    fda recalls · 11d ago↗ source
  • Opinion: Beware the unintended consequences of testosterone screening for military servicemembers
    “I fear that the widespread rollout of testosterone screening may lead to some surprising and unintended consequences,” writes a urologist who studies testosterone.
    STAT · 12d ago↗ source
  • Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidine
    FOR IMMEDIATE RELEASE – July 18th, 2026 – Panoli, Gujarat, Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) is voluntarily recalling four lots of Cetirizine Hyd…
    fda recalls · 12d ago↗ source
  • Opinion: STAT readers on the value of primary care, obesity as a disease, and more
    “The real opportunity is to move beyond policies and narratives that pit specialties against one another,” presidents of the AAFP, ACP, and AAP write.
    STAT · 13d ago↗ source
  • Fayus Inc., dba Yusol International Foods Expands Recall of OLA-OLA POUNDED YAM Due to Undeclared Milk Allergen
    Fayus Inc., doing business as Yusol International Foods (Sacramento, CA) is expanding its recall of OLA-OLA POUNDED YAM to include product sizes 2lbs, 4lbs, 5lbs, and 10lbs due to product labeling…
    fda recalls · 13d ago↗ source
  • Opinion: What the 20th-century war on smog tells us about today’s wildfire smoke
    The evolution of air pollution policy shows how to respond to the dangerous haze caused by Canadian wildfires, experts write in opinion piece.
    STAT · 13d ago↗ source
  • Quitting smoking is hard. A Medicare change may push doctors to give more help
    Physicians who offer counseling on quitting cigarettes and alcohol during patient visits would get a 19% increase in reimbursement under a proposed Medicare change.
    STAT · 14d ago↗ source
  • Jasper gets a lifeline in merger with immune drugmaker Kira
    The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.
    BioPharma Dive · 14d ago↗ source
  • India’s life sciences sector at turning point for innovation: Report
    Structural gaps in areas including clinical execution and funding limit India’s ability to scale up innovation, according to a report from Boston Consulting Group and HealthKois.
    BioSpace · 14d ago↗ source
  • Lettuce at Taco Bell in five states confirmed as a source of diarrhea-causing parasite
    Health officials have identified lettuce from Mexico served at Taco Bell locations across five U.S. states as a source of the outbreak of diarrhea-causing parasite cyclospora.
    STAT · 14d ago↗ source
  • STAT+: The end for GSK’s chronic cough treatment
    Sonothera's ultrasound gene therapy delivery, a new Alzheimer's drug controversy, and more biotech news from The Readout
    STAT · 14d ago↗ source
  • Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
    The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched…
    BioPharma Dive · 14d ago↗ source
  • Compounders maintain a firm grip on the GLP-1 market
    Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.
    BioPharma Dive · 14d ago↗ source
  • GSK shelves cough drug acquired in $2B deal
    Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
    BioPharma Dive · 14d ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 14d ago↗ source